Wound healing after excision of subcutaneous tumors treated with near-infrared photoimmunotherapy.
Animals
Combined Modality Therapy
/ methods
Disease Models, Animal
Humans
Immunotherapy
/ methods
Mice
Neoplasm Recurrence, Local
Neoplasm Transplantation
Phototherapy
/ methods
Postoperative Care
Postoperative Complications
Reactive Oxygen Species
/ analysis
Stomach Neoplasms
/ pathology
Tensile Strength
/ physiology
Wound Healing
/ physiology
Xenograft Model Antitumor Assays
near-infrared photoimmunotherapy
neoadjuvant
reactive oxygen species
surgery
wound healing
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
22
05
2020
accepted:
02
06
2020
pubmed:
25
6
2020
medline:
5
6
2021
entrez:
25
6
2020
Statut:
ppublish
Résumé
Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer therapy that employs a combination of infrared light and tumor-targeted monoclonal antibody-photoabsorber conjugates to cause both direct tumor necrosis and immunogenic cell death. NIR-PIT may have potential in the perioperative setting before surgery, and therefore it is important to know the effect of NIR-PIT on wound healing. Fifty mice were implanted with subcutaneous xenografts of N87 human gastric cancer cells, and tumors were excised after reaching a predetermined size. After excision, 30 mice were split into three groups: Controls, NIR-PIT 1 day prior to surgery and NIR-PIT 3 days prior to surgery. The quantity of reactive oxygen species (ROS) in each wound was measured on Postoperative Days 2 and 4, and mice were monitored weekly for 4 weeks for evidence of local tumor recurrence as well as clinical evidence of wound healing complications (eg, dehiscence, infection). The remaining 20 mice (10 controls, 10 treated with NIR-PIT 1 day prior to surgery) were sacrificed on either Postoperative Day 7 or 14, the skin around wounds were excised, and tensile strength was measured with a digital force gauge. There were no significant differences between treatment and control groups with respect to wound ROS levels, wound tensile strength, local tumor recurrence, or postoperative complication rates (P > .05). In conclusion, neoadjuvant (pre-operative) NIR-PIT shows no evidence of adverse wound healing effects, and it is likely a safe adjunctive treatment to surgery. Postoperative use of NIR-PIT merits investigation.
Identifiants
pubmed: 32579795
doi: 10.1002/cam4.3247
pmc: PMC7433815
doi:
Substances chimiques
Reactive Oxygen Species
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5932-5939Subventions
Organisme : Intramural NIH HHS
ID : ZIA BC011513
Pays : United States
Informations de copyright
© Published 2020. This article is a U.S. Government work and is in the public domain in the USA. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Biomaterials. 2011 Mar;32(7):1796-801
pubmed: 21146868
Free Radic Biol Med. 2013 Dec;65:1310-1314
pubmed: 24080119
Cancer Med. 2020 Aug;9(16):5932-5939
pubmed: 32579795
Br J Cancer. 1999 Mar;79(9-10):1392-8
pubmed: 10188881
MethodsX. 2018 Apr 16;5:337-344
pubmed: 30050753
Nat Med. 2011 Nov 06;17(12):1685-91
pubmed: 22057348
J Invest Dermatol. 2011 Feb;131(2):518-28
pubmed: 20927125
Cancer Res. 1994 Aug 15;54(16):4334-41
pubmed: 7519120
Ann Surg. 1975 Jun;181(6):842-6
pubmed: 1138634
Am J Surg. 2004 May;187(5A):11S-16S
pubmed: 15147986
Crit Rev Oncol Hematol. 2014 Jan;89(1):16-26
pubmed: 23958676
Clin Dermatol. 2007 Jan-Feb;25(1):9-18
pubmed: 17276196
J Biomed Biotechnol. 2011;2011:969618
pubmed: 21151647
J Vis Exp. 2018 Nov 17;(141):
pubmed: 30507922
Int Wound J. 2017 Feb;14(1):89-96
pubmed: 26688157
J Trauma. 1994 Jun;36(6):810-3; discussion 813-4
pubmed: 8015002
J Invest Dermatol. 2001 Jul;117(1):3-15
pubmed: 11442744
Wound Repair Regen. 2000 Mar-Apr;8(2):83-96
pubmed: 10810034
Wound Repair Regen. 1998 Mar-Apr;6(2):127-34
pubmed: 9776855
Br J Surg. 1998 Apr;85(4):444-60
pubmed: 9607524
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Cancer Med. 2016 Jul;5(7):1526-34
pubmed: 27167827
Lasers Med Sci. 2010 Sep;25(5):761-6
pubmed: 20496092
Photomed Laser Surg. 2005 Oct;23(5):485-92
pubmed: 16262579
Clin Cancer Res. 2019 Jun 15;25(12):3561-3571
pubmed: 30890547
Cancer Immunol Res. 2019 Mar;7(3):401-413
pubmed: 30683733
Clin Dermatol. 2007 Jan-Feb;25(1):19-25
pubmed: 17276197
Eur Cell Mater. 2012 Sep 24;24:249-65
pubmed: 23007910
J Surg Res. 2015 Jul;197(1):5-11
pubmed: 25799527
Cancer Immunol Res. 2020 Mar;8(3):345-355
pubmed: 31953245
Lasers Med Sci. 2016 Nov;31(8):1683-1689
pubmed: 27495128
Oncotarget. 2017 Feb 7;8(6):10425-10436
pubmed: 28060726
Eur Surg Res. 2009;43(1):61-5
pubmed: 19451720
Wound Repair Regen. 2016 Jan-Feb;24(1):26-34
pubmed: 26562746
Mol Pharm. 2017 Dec 4;14(12):4628-4635
pubmed: 29135265
Acc Chem Res. 2019 Aug 20;52(8):2332-2339
pubmed: 31335117
Gastric Cancer. 2019 May;22(3):463-472
pubmed: 30171392